Conduit Pharmaceuticals (CDT) Institutional Ownership $0.56 0.00 (-0.36%) As of 04:00 PM Eastern Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Conduit Pharmaceuticals (NASDAQ:CDT)CurrentInstitutional OwnershipPercentage3.29%Number ofInstitutional Buyers(last 12 months)4TotalInstitutional Inflows(last 12 months)$10.68MNumber ofInstitutional Sellers(last 12 months)0 Get CDT Insider Trade Alerts Want to know when executives and insiders are buying or selling Conduit Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Conduit Pharmaceuticals Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails2/17/2025Citadel Advisors LLC526,268$36K0.0%+177.0%51.094% 2/13/2025Barclays PLC892,350$61K0.0%+6.5%86.636% 2/12/2025Geode Capital Management LLC584,984$40K0.0%+36.8%56.795% 1/30/2025 Rhumbline Advisers1,028,702$71K0.0%+5,034.0%1.000% (Data available from 1/1/2016 forward) CDT Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of CDT shares? During the previous two years, the following institutional investors and hedge funds held shares of Conduit Pharmaceuticals shares: Rhumbline Advisers ($71K), Barclays PLC ($61K), and Geode Capital Management LLC ($40K), Citadel Advisors LLC ($36K).Learn more on CDT's institutional investors. What percentage of Conduit Pharmaceuticals stock is owned by institutional investors? 3.29% of Conduit Pharmaceuticals stock is owned by institutional investors. Learn more on CDT's institutional investor holdings. Which institutional investors have been buying Conduit Pharmaceuticals stock? The following institutional investors have purchased Conduit Pharmaceuticals stock in the last 24 months: Rhumbline Advisers ($1.01M), Citadel Advisors LLC ($336.28K), Geode Capital Management LLC ($157.31K), and Barclays PLC ($54.52K). How much institutional buying is happening at Conduit Pharmaceuticals? Institutional investors have bought a total of 1,556,773 shares in the last 24 months. This purchase volume represents approximately $10.68M in transactions. Related Companies IN8bio Major Shareholders ImmunoPrecise Antibodies Major Shareholders TherapeuticsMD Major Shareholders GeoVax Labs Major Shareholders Moleculin Biotech Major Shareholders Trinity Biotech Major Shareholders Calidi Biotherapeutics Major Shareholders Cellectar Biosciences Major Shareholders Abpro Major Shareholders Marker Therapeutics Major Shareholders This page (NASDAQ:CDT) was last updated on 4/30/2025 by MarketBeat.com Staff From Our Partners"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...Paradigm Press | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredChina’s next move could destroy U.S. techThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Conduit Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Conduit Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
